ERCC1高表达可能与胃癌对铂类辅助化疗的耐药性相关。
Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer.
作者信息
Wan Jiayi, Chao Lin, Lee Arier C, Chen Qi
机构信息
a Department of Pathology , Wuxi No. 2 People's Hospital, Nanjing Medical University , Wuxi , China.
b Department of General Surgery , Wuxi No. 2 People's Hospital, Nanjing Medical University , Wuxi , China.
出版信息
Cancer Invest. 2017 Feb 7;35(2):85-91. doi: 10.1080/07357907.2016.1267741. Epub 2017 Jan 19.
Potential predictive biomarker(s) to respond to chemotherapy in gastric cancer are unclear. Excision repair cross-complementing 1 (ERCC1), a DNA repair enzyme, is associated with clinical outcomes in gastric cancer. Here, we investigated the expression of ERCC1 in gastric cancer with platinum-based chemotherapy after surgery, and the association between ERCC1 expression and clinical parameters was analyzed. Our data showed that high levels of ERCC1 expression were positively associated with resistance to platinum-based chemotherapy but not with lymph node metastasis and pathological stage. In addition, patients with resistance to platinum-based chemotherapy probably had lymph node metastasis and pathological stage.
目前尚不清楚胃癌中对化疗有反应的潜在预测生物标志物。切除修复交叉互补基因1（ERCC1）是一种DNA修复酶，与胃癌的临床结局相关。在此，我们研究了ERCC1在胃癌术后铂类化疗中的表达情况，并分析了ERCC1表达与临床参数之间的关联。我们的数据显示，ERCC1高表达与铂类化疗耐药呈正相关，但与淋巴结转移和病理分期无关。此外，铂类化疗耐药的患者可能有淋巴结转移和病理分期。
Zotero 插件